7V3 Stock Overview A biotechnology company, develops antibody-based treatments for life threatening diseases. More details
Rewards Risk Analysis + 2 more risks
See All Risk Checks Capture your thoughts, links and company narrative
Cantargia AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Cantargia Historical stock prices Current Share Price SEK 0.11 52 Week High SEK 0.46 52 Week Low SEK 0.11 Beta 1.76 1 Month Change -19.74% 3 Month Change -18.08% 1 Year Change -59.66% 3 Year Change -93.30% 5 Year Change -94.73% Change since IPO -93.23%
Recent News & Updates
Cantargia AB (publ) Announces CEO Changes Feb 07
Cantargia AB (publ) Announces CEO Changes Feb 06
Cantargia AB (publ) Publishes Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer Dec 19
Cantargia AB (publ) Expands CAN10 Phase 1 Clinical Program Building on Positive Results Nov 29
New major risk - Revenue and earnings growth Nov 17 Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025 See more updates
Cantargia AB (publ) Announces CEO Changes Feb 07
Cantargia AB (publ) Announces CEO Changes Feb 06
Cantargia AB (publ) Publishes Preclinical Effects and Clinical Monotherapy Results on Nadunolimab in Pancreatic Cancer in Journal for Immunotherapy of Cancer Dec 19
Cantargia AB (publ) Expands CAN10 Phase 1 Clinical Program Building on Positive Results Nov 29
New major risk - Revenue and earnings growth Nov 17 Cantargia AB (publ) to Report First Half, 2025 Results on Aug 21, 2025
Cantargia AB (publ), Annual General Meeting, May 15, 2025 Nov 14 Cantargia AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 169.910183 million. Nov 07
Cantargia Presents Promising Preclinical Results on Nadunolimab with Antibody-Drug Conjugates At Major Immuno-Oncology Conference Nov 06
Cantargia Reports New Results from Clinical Studies Investigating Nadunolimab in Several Forms of Cancer; Supporting Ongoing Strategies Oct 29
Cantargia Reports New Positive Results on Biomarkers and Safety in CAN10 Phase 1 Clinical Study Oct 12
Cantargia Announces the Publication of the Results Using Nadunolimab Combination Therapy in Advanced/Metastatic Pancreatic Cancer (PDAC) in the Scientific Journal Clinical Cancer Research Oct 10 Cantargia AB (publ) to Report Q1, 2025 Results on May 13, 2025
Cantargia Announces New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors Sep 09
Cantargia AB (publ) Reports Timelines for Nadunolimab Clinical Trials in Leukemia and Triple Negative Breast Cancer Aug 27
Cantargia Announces Resignation of Liselotte Larsson as Chief Operating Officer Jul 22
Cantargia AB (Publ) Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10 Jun 15
Cantargia AB (Publ) Announces Appointment of Ton Berkien as Chief Business Officer, Effective October 1, 2024 Jun 13
Insufficient new directors Jun 02
Cantargia Presents New Positive Clinical Data on Nadunolimab Counteracting Chemotherapy Induced Neuropathy May 24
Forecast to breakeven in 2026 May 22
New major risk - Revenue and earnings growth May 21
Cantargia Publishes New Data on the Can10 Antibody, Detailing Its Interaction with IL1RAP and Functional Inhibition Apr 18
Cantargia AB (publ) Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal Apr 11
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis Apr 03
Cantargia AB (publ) Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia Mar 27
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis Mar 15
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer Mar 08
Forecast to breakeven in 2026 Feb 25
New major risk - Financial position Feb 23
Cantargia AB (publ) to Report Fiscal Year 2024 Results on Feb 21, 2025 Feb 22
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab Feb 21
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy Feb 13
Cantargia Reports Phase I Clinical Progress in the CAN10 Project Jan 10
Cantargia Reports New Preclinical Data Confirming the Potential of Nadunolimab and Can10 Nov 25
New major risk - Revenue and earnings growth Nov 17
New major risk - Financial position Nov 12 Cantargia AB (publ) to Report Q2, 2024 Results on Aug 28, 2024
Cantargia AB (publ), Annual General Meeting, May 23, 2024 Nov 04
New minor risk - Shareholder dilution Nov 02
Cantargia Presents New Clinical Data Further Supporting Nadunolimab's Antitumor Activity and A Key Role of Its Target IL1RAP in Pancreatic Cancer Sep 28
Cantargia Reports New Preclinical Data on nadunolimab Potential to Enhance Anti-Tumor Effect of Immunotherapy Presented at CRI-ENCI-AACR Sep 21
Cantargia AB (publ) Announces New Nadunolimab Clinical Trial in Leukemia Financed by External US Grant Sep 19
Cantargia AB (publ)Expands Clinical Pipeline and Starts Treatment in Second Program, CAN10, for Autoimmune Diseases Sep 06
No longer forecast to breakeven Aug 24
Cantargia AB (publ) to Report Q1, 2024 Results on May 21, 2024 Aug 22
Cantargia AB (publ) Receives Regulatory Approval to Start Phase I Clinical Trial for CAN10 Aug 11
Cantargia Publishes ASCO 2023 Poster on Promising Nadunolimab Efficacy in Non-Small Cell Lung Cancer Jun 05 Cantargia AB (publ) Promotes David Liberg to Chief Scientific Officer
Cantargia Extends Development of Nadunolimab in Pancreatic Cancer with New Controlled Phase IIb Clinical Trial Following Strong Phase IIb Efficacy Results May 17
Cantargia Appoints Patrik Renblad as Chief Financial Officer Feb 02
Cantargia AB (publ) Successfully Concludes Toxicity Study with Can10 Antibody Ahead of Phase I Clinical Trial Application Jan 14
Cantargia AB (Publ) Announces Nomination Committee Appointments Nov 22
Cantargia's CAN10 Demonstrates Positive Activity in Systemic Sclerosis Models in New Data Presented At ACR Convergence 2022 Nov 09
Cantargia AB (Publ) Presents New Data At SITC 2022 Supporting Nadunolimab's Promising Antitumor Clinical Efficacy Nov 08
Cantargia Reaches Recruitment Milestone and Focuses Nadunolimab Development on Upcoming Randomized Studies Oct 15 Cantargia AB (publ) to Report Q2, 2023 Results on Aug 22, 2023
Cantargia Reports First Non-Squamous NSCLC Patient Treated with Nadunolimab, Keytruda® and Chemotherapy Sep 22
Cantargia Reports Preclinical Data Demonstrating Unique Treatment Effects of nadunolimab on Pancreatic Cancer Stromal Cells Sep 14
Cantargia AB (Publ) Publishes Preclinical Data on Strong Anti-Tumor Efficacy of Nadunolimab in Combination with Chemotherapy Aug 30
Cantargia Reports New Positive Preclinical Efficacy Data for CAN10 Supporting Development in Myocarditis Jul 27
Cantargia Receives USPTO Notice of Allowance for Composition of Matter Patent on Antibody CAN10 Jul 22
Cantargia AB (Publ) Announces Executive Changes Jul 09
Cantargia Announces ASCO 2022 Presentation Strengthens Positive Phase IIa interim results for nadunolimab in NSCLC May 28
Cantargia AB (publ) Presents Clinical Interim Results At ASCO 2022 Highlighting the Potential of Nadunolimab in Combination with Checkpoint Inhibitor May 27
Cantargia AB (publ) Reports Positive Preclinical Effects in Atherosclerosis Demonstrating Potential of Can10 in Cardiovascular Disease May 23
Forecast breakeven date pushed back to 2024 May 10
Forecast breakeven date pushed back to 2024 Mar 13
Cantargia Reports Positive Preclinical Efficacy Data for CAN10 Demonstrating Anti-Fibrotic and Anti-Inflammatory Effects in Systemic Sclerosis Mar 03
Cantargia AB (Publ) Reports Encouraging New CAN10 Toxicology Results and Schedules Phase I Trial for 2023 Feb 24
Cantargia AB Reports Treatment of First Non-Squamous Non-Small Cell Lung Cancer Patient in New Arm of CANFOUR Study Feb 05
Cantargia Reports Positive Safety Data from Cirifour Clinical Study on Nadunolimab and Pembrolizumab Combination Feb 04
Cantargia AB (Publ) Reports Treatment of First Triple Negative Breast Cancer Patient in TRIFOUR Study Jan 16
Cantargia Advances Nadunolimab Against Pancreatic Cancer in the Pancan Precision Promise[Sm] Phase 2/3 Clinical Trial Jan 04
Cantargia AB (publ) Reports Updated Encouraging Survival Data from CANFOUR Trial with Nadunolimab and Chemotherapy in Pancreatic Cancer Dec 30
Cantargia AB (publ) Reports Positive Results for Can10 Antibody in Preclinical Systemic Sclerosis Model Dec 15
Forecast to breakeven in 2023 Oct 31
Forecast to breakeven in 2023 Sep 23
Cantargia AB (Publ) Announces New Positive Interim Results on Nadunolimab Combination Therapy in NSCLC Published in Abstract for the Annual ESMO Congress Sep 13 Cantargia AB Completes Patient Recruitment to the Phase IIa Pancreatic Cancer Extension Cohort in the CANFOUR Study
Cantargia AB Reports Preclinical Data Highlighting Advantages of Nadunolimab Mechanism of Action Aug 31
Cantargia AB Reports First Patient Treated in CAPAFOUR Study Investigating Combination of Nadunolimab with FOLFIRINOX in Pancreatic Cancer Aug 27
Cantargia Expands CIRIFOUR Trial After Successful Completion of Recruitment in the Pembrolizumab Combination Arm Aug 20
Cantargia Advances Development of Nadunolimab in Triple Negative Breast Cancer Through Submission of Clinical Protocol for TRIFOUR Study Jul 02
Cantargia AB (publ) Broadens the Development of Nadunolimab in Three Forms of Cancer and Submits Application for the Phase I/II Clinical Trial CESTAFOUR Jun 30
Cantargia Receives Regulatory Approval to Start Clinical Trial Investigating Nadunolimab and FOLFIRINOX in Pancreatic Cancer Jun 09
Chief Financial Officer recently bought €23k worth of stock Jun 01
Cantargia AB (Publ) Reports Positive Results in Ongoing Phase IIa Clinical Trial in Pancreatic Cancer Using Nadunolimab and Chemotherapy May 21
Cantargia AB Presents New Preclinical Data Showing Unique Improvement of Heart Function in Myocarditis Using Antibody CAN10 May 11
Cantargia AB (Publ) Advance Development of Antibody Can04 by A New Clinical Trial in Triple Negative Breast Cancer May 07 Shareholder Returns 7V3 DE Biotechs DE Market 7D -3.8% -12.3% -0.6% 1Y -59.7% -15.3% 14.8%
See full shareholder returns
Return vs Market: 7V3 underperformed the German Market which returned 14.8% over the past year.
Price Volatility Is 7V3's price volatile compared to industry and market? 7V3 volatility 7V3 Average Weekly Movement 18.0% Biotechs Industry Average Movement 8.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.6%
Stable Share Price: 7V3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 7V3's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Cantargia AB (publ), a biotechnology company, develops antibody-based treatments for life threatening diseases. The company is developing CAN04 (nadunolimab), an interleukin-1 receptor accessory protein (IL1RAP) binding antibody, which is in Phase II clinical trial for the treatment of pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer; and CAN10, an antibody against IL1RAP, which is in preclinical phase for the treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis. It also develops CANxx, an IL1RAP-based antibody platform.
Show more Cantargia AB (publ) Fundamentals Summary How do Cantargia's earnings and revenue compare to its market cap? 7V3 fundamental statistics Market cap €24.69m Earnings (TTM ) -€14.50m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 7V3 income statement (TTM ) Revenue SEK 0 Cost of Revenue SEK 0 Gross Profit SEK 0 Other Expenses SEK 161.65m Earnings -SEK 161.65m
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 13, 2025
Earnings per share (EPS) -0.88 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio 0%
How did 7V3 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/22 09:28 End of Day Share Price 2025/02/21 00:00 Earnings 2024/12/31 Annual Earnings 2024/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Cantargia AB (publ) is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Arvid Necander Carnegie Investment Bank AB Soo Romanoff Edison Investment Research null null Life Sciences Research International BV
Show 3 more analysts 
